CA2889494C - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome - Google Patents

Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome Download PDF

Info

Publication number
CA2889494C
CA2889494C CA2889494A CA2889494A CA2889494C CA 2889494 C CA2889494 C CA 2889494C CA 2889494 A CA2889494 A CA 2889494A CA 2889494 A CA2889494 A CA 2889494A CA 2889494 C CA2889494 C CA 2889494C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2889494A
Other languages
English (en)
French (fr)
Other versions
CA2889494A1 (en
Inventor
Roland Werner BURLI
William Rameshchandra Krishna ESMIEU
Christopher James Lock
Karine Fabienne MALAGU
Andrew Pate Owens
William Edward HARTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Usher III Initiative Inc
Original Assignee
Usher III Initiative Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usher III Initiative Inc filed Critical Usher III Initiative Inc
Publication of CA2889494A1 publication Critical patent/CA2889494A1/en
Application granted granted Critical
Publication of CA2889494C publication Critical patent/CA2889494C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2889494A 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome Active CA2889494C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261718611P 2012-10-25 2012-10-25
US61/718,611 2012-10-25
US201361775402P 2013-03-08 2013-03-08
US61/775,402 2013-03-08
PCT/US2013/066939 WO2014066836A1 (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Publications (2)

Publication Number Publication Date
CA2889494A1 CA2889494A1 (en) 2014-05-01
CA2889494C true CA2889494C (en) 2018-12-18

Family

ID=50545356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2889494A Active CA2889494C (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Country Status (10)

Country Link
EP (1) EP2911671B1 (enExample)
JP (1) JP6291502B2 (enExample)
AU (1) AU2013334139B2 (enExample)
CA (1) CA2889494C (enExample)
ES (1) ES2687854T3 (enExample)
HU (1) HUE039970T2 (enExample)
IL (1) IL238288B (enExample)
PL (1) PL2911671T3 (enExample)
WO (1) WO2014066836A1 (enExample)
ZA (1) ZA201502655B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2834049C (en) 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
PL2912038T3 (pl) * 2012-10-25 2019-02-28 Usher Iii Initiative, Inc. Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera
WO2017045955A1 (en) * 2015-09-14 2017-03-23 Basf Se Heterobicyclic compounds
KR20200033249A (ko) 2017-06-05 2020-03-27 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
AU2019294478B2 (en) 2018-06-27 2023-03-23 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020161209A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
WO2020161208A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
EP4466264A1 (en) * 2022-01-19 2024-11-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Geralexin and uses thereof for the treatment of retinal degenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206723D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel compounds
US20090306045A1 (en) * 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
JP2011503103A (ja) * 2007-11-07 2011-01-27 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送の調節方法
CA2834049C (en) * 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
PL2912038T3 (pl) * 2012-10-25 2019-02-28 Usher Iii Initiative, Inc. Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera

Also Published As

Publication number Publication date
AU2013334139A1 (en) 2015-04-30
WO2014066836A1 (en) 2014-05-01
AU2013334139B2 (en) 2017-08-03
EP2911671B1 (en) 2018-06-27
ZA201502655B (en) 2017-11-29
EP2911671A1 (en) 2015-09-02
EP2911671A4 (en) 2016-09-14
HK1214180A1 (en) 2016-07-22
CA2889494A1 (en) 2014-05-01
IL238288A0 (en) 2015-06-30
ES2687854T3 (es) 2018-10-29
JP2015535257A (ja) 2015-12-10
JP6291502B2 (ja) 2018-03-14
HUE039970T2 (hu) 2019-02-28
PL2911671T3 (pl) 2018-11-30
IL238288B (en) 2018-04-30

Similar Documents

Publication Publication Date Title
CA2889494C (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9783545B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP7208142B2 (ja) Rhoキナーゼ阻害剤としてのチロシンアミド誘導体
CN102695710B (zh) 三环吡唑胺衍生物
US9187464B2 (en) TRPV4 antagonists
RU2666349C2 (ru) Новое конденсированное пиримидиновое соединение или его соль
CA3207392A1 (en) Cdk inhibitor
TW201726619A (zh) 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物
AU2017269726B2 (en) Tricyclic heterocylic derivatives
AU2012249801B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome
TWI671299B (zh) 作為rsv抗病毒化合物之螺脲化合物
AU2013209586A1 (en) Substituted pyrimidine compounds and their use as SYK inhibitors
JP2023539985A (ja) 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体
US11981658B2 (en) Substituted aminopyridine compounds as EGFR inhibitors
CA2889537C (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
TW202517653A (zh) 治療自體免疫疾病之大環
HK1214180B (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
WO2025057126A1 (ko) Sting(인터페론 유전자 자극인자) 활성화제로서의 헤테로 고리 유도체 및 이를 포함하는 약학적 조성물
HK1171742A (en) Tricyclic pyrazol amine derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150423